View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Tesaro, Inc.

Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian Cancer

Release Date: October 31, 2017
Expiration Date: October 31, 2018
Media: Internet - based


Activity Overview

New clinical treatment options for patients with ovarian cancer continue to emerge at a rapid pace, including several options that target the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) family of enzymes. FDA approval has been granted for several of these agents, altering the treatment landscape. In order to optimize clinical decision-making regarding medical therapies for ovarian cancer, it is imperative for clinicians to be aware of the latest data pertaining to PARP inhibition. This activity is designed to enhance knowledge of the mechanistic rationale for the application of PARP inhibitors in the treatment of patients with ovarian cancer, as well as strategies to personalize care for these patients and mitigate adverse events associated with this treatment modality. The perspectives of leading clinical experts in the management of ovarian cancer will be provided throughout this activity.

CME/CE Activity Table of Contents

  • Translating Tumor Characteristics to PARP Inhibitor Development in Ovarian Cancer
  • Assessing Methods to Optimize Personalized Care in Ovarian Cancer
  • Current Strategies to Optimize PARP Inhibition in Multiple Lines of Care
  • Management of Treatment-Related Toxicities With PARP Inhibitor Use

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This activity is directed toward medical, surgical and radiation oncologists who treat or manage patients with ovarian cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe how PARP inhibition strategies have been applied to the management of recurrent ovarian cancer
  • Discuss how care can be personalized via the use of testing strategies in BRCA-mutant and non—BRCA-mutant patient populations with ovarian cancer
  • Examine the current emerging roles of PARP inhibitors (PARPis) in maintenance therapy for ovarian cancer
  • Describe effective strategies to proactively plan for and manage treatment-related toxicities in the setting of ovarian cancer

Faculty, Staff, and Planners' Disclosures


Michael Birrer, MD, PhD
Professor of Medicine
Division of Hematology & Oncology
UAB Comprehensive Cancer Center
Birmingham, AL

Disclosure: Grant/Research Support – Roche Laboratories.

Susan Campos, MD
Assistant Professor of Medicine
Harvard Medical School
Dana Farber Cancer Institute
Boston, MA

Disclosure: Consultant – Advisory Board, Clovis.

Maurie Markman, MD
President, Medicine & Science
Cancer Treatment Centers of America
Clinical Professor of Medicine
Drexel University College of Medicine
Philadelphia, PA

Disclosure: Celgene; Speaker’s Bureau – Genentech, AstraZeneca, Clovis, Tesaro, Inc.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By